- $641.23m
- $487.49m
U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
Brief: Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For Treatment Of Pancreatic Cancer
Candel Therapeutics jumps on orphan drug tag for lead cancer therapy
Brief: Candel Therapeutics Presents Preclinical Data On Immunotherapy Candidate For Induction Of Tertiary Lymphoid Structures In Solid Tumors
Brief: Candel Therapeutics Q4 Net Income USD -11.095 Million
U.S. STOCKS ON THE MOVE-JetBlue Airways, LPL Financial, Nvidia
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
Candel Therapeutics up on receiving fast track tag from FDA
Brief: Candel says CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
Brief: Candel Therapeutics Says Jason A. Amello To Resign As Chief Financial Officer In January
U.S. STOCKS ON THE MOVE-Expedia, Moderna, HubSpot
U.S. STOCKS ON THE MOVE-C4 Therapeutics, Eagle Bulk, SilverBow Resources
U.S. STOCKS ON THE MOVE-Wyndham Hotels, Alphabet, Candel Therapeutics
Candel Therapeutics gains on FDA's 'fast track' tag for cancer therapy
Brief: Candel Therapeutics Receives FDA Fast Track Designation For Can-2409 In Pancreatic Cancer
Brief: Candel Therapeutics Announces Restructuring To Prioritize Resources On Key Value Drivers For Expanded Development Of Can-3110
Brief: Candel Therapeutics Q3 Net Income USD -8.435 Million
Brief: Candel Therapeutics Reports Encouraging Initial Survival Data From Phase 2 Clinical Trial Of Can-2409 In Non-Small Cell Lung Cancer